Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

"I am excited to join Rigel as it continues to advance its development pipeline," said Dr. Frohlich. "I believe the IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients ...

"I believe the IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients with lower-risk myelodysplastic syndrome and glioma, respectively. I look forward to ...

We continue to evaluate R289, our dual IRAK1 and 4 inhibitor, in an ongoing Phase 1b study in patients with lower-risk MDS. We presented encouraging initial safety and efficacy data from that ...

Macrophages play a central role in initiating, maintaining, and terminating inflammation. For that, macrophages respond to various external stimuli in changing environments through signaling pathways ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were $40 ...

First, investigators performed a genome-wide CRISPR knockout screen to identify proteins that regulate VISTA levels; the team found that the presence of proteins AhR and IRAK1 appeared to have an ...